BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Kenvue Stock Selloff Presents Buying Opportunity Amid Tylenol Controversy
Kenvue Stock Selloff Presents Buying Opportunity Amid Tylenol Controversy
10
3
BTCCSquare news:
Kenvue shares have plummeted 25% over six months following renewed scrutiny of a potential link between Tylenol use during pregnancy and autism risk. The TRUMP administration's September 22 warning amplified existing concerns, though the allegations had circulated for months prior.
Despite the health controversy, analysts see an oversold condition in KVUE stock. The Johnson & Johnson spinoff maintains a diversified portfolio of consumer health brands and now offers a 5% dividend yield. Wall Street projects 30% upside potential over the next year, suggesting the market may be overpenalizing the company for single-product risks.
By:
